Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Baylor Breast Care Center
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05319873CT.gov Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04569747CT.gov A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04398914CT.gov Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04266249CT.gov CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | — | Active Not Recruiting | — | — | — |
NCT03595592CT.gov Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pertuzumab (this asset) | Baylor Breast Care Center | P3 | BB · 67 |
| Tamoxifen | University of California, San Francisco | P4 | BBB |
| Letrozole | Emory University | P4 | BBB |
| Exemestane | University of California, San Francisco | P4 | BBB |
| Anastrozole | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Carboplatin | Baylor Breast Care Center | P3 | BB |
| Fulvestrant | Massachusetts General Hospital | P2 | BB |
| Trastuzumab | Massachusetts General Hospital | P3 | BB |
| Capecitabine | Dr. Tabassum Wadasadawala | P3 | BB |
+42 more in the Invasive Breast Carcinoma cohort
Other indications for Pertuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BBB · 75 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 72 |
| Breast Cancer | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pertuzumab in Invasive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-neu-receptor-human-mouse-monoclonal-2c4-heavy-chain-disulfide-with-human-mouse-monoclonal-2c4-kappa-chain-dimer-invasive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →